ZLN005, PGC-1α Transcriptional Activator

ZLN005 is a potent and selective small molecule PGC-1α transcriptional activator. ZLN005 stimulates the expression of PGC-1α and downstream genes in skeletal muscle cells, improving glucose utilization and fatty acid oxidation.

Product information

CAS Number: 49671-76-3

Molecular Weight: 250.34

Formula: C17H18N2

Synonym:

2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazole

MFCD01560221

Chemical Name: 2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazole

Smiles: CC(C)(C)C1C=CC(=CC=1)C1NC2=CC=CC=C2N=1

InChiKey: LQUNNCQSFFKSSK-UHFFFAOYSA-N

InChi: InChI=1S/C17H18N2/c1-17(2,3)13-10-8-12(9-11-13)16-18-14-6-4-5-7-15(14)19-16/h4-11H,1-3H3,(H,18,19)

Technical Data

Appearance: white to off-white solid powder

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO 37 mg/mL (147.80 mM); Ethanol 2 mg/mL (7.99 mM); Water Insoluble

Shipping Condition: Room temperature in continental US; may vary elsewhere.

Storage Condition: -20^oCfor 3 years; 4^oC 2 years

Shelf Life: ≥1080 days if stored properly.

Stock Solution Storage: -80°C for 6 months -20°C for 1 month

Drug Formulation: This drug may be formulated in DMSO

HS Tariff Code: 2934.99.9001

How to use

In Vitro:

ZLN005 was used at 10-20 µM final concentration in various in vitro assays.

In Vivo:

ZLN005 was orally administrated in db/db mice at 15 mg/kg once per day for 6 weeks.

References:

1. Zhang LN, et al. Novel small-molecule PGC-1α transcriptional regulator with beneficial effects on diabetic db/db mice. (2013) Diabetes. 62(4):1297-307.

Products are for research use only. Not for human use.